Samer Nakhle, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1841281771
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $393,375 of the $466,230 with a category attached, or 84.4%. Lilly USA, LLC accounts for 68.8% of it on its own, with 54 other manufacturers making up the rest. Reporting peaked in 2022 at $108,074 and has fallen 69.2% since, to $33,314 in 2025. Among endocrinology, diabetes & metabolism clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,202 payments — averaging $387.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$321K
- Novo Nordisk$104K
- Novo Nordisk AS$11K
- Eli Lilly$10K
- Ascendis Pharma Endocrinology Inc$8K
- AbbVie$3K
- plus $8K from 49 others
Across 4,172 payments — averaging $3404.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8M
- Amgen$1.5M
- Novo Nordisk AS$1.4M
- Dexcom, Inc.$1.3M
- AbbVie$619K
- Sanofi US Services Inc.$546K
- plus $880K from 20 others
What the payments were for
- Consulting fees$17,5104%
- Speaking & faculty fees$393,37584%
- Travel & lodging$34,5777%
- Food & beverage$20,7564%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$466,230 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 468 | $638,112 |
| JardianceEmpagliflozin | 377 | $371,787 |
| MounjaroTirzepatide | 226 | $276,780 |
| TrulicityDulaglutide | 175 | $265,721 |
| ProliaDenosumab | 95 | $165,721 |
| Tresiba Flextouch U-100Insulin Degludec | 225 | $143,880 |
| Tresiba Flextouch U-200Insulin Degludec | 113 | $107,342 |
| FarxigaDapagliflozin Propanediol | 84 | $94,768 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 75 | $92,896 |
| Humalog Kwikpen U-100Insulin Lispro | 228 | $75,938 |
| Novolog FlexpenInsulin Aspart | 246 | $75,062 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $70,135 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $69,425 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 81 | $68,432 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 104 | $56,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $103,704 | $692,899551 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $320,760 | $557,983441 claims |
| Boehringer IngelheimJardiance, Tradjenta | $316 | $385,249388 claims |
| AmgenProlia | $979 | $165,72195 claims |
| AstraZenecaFarxiga | $652 | $94,76884 claims |
| MerckJanuvia | $12 | $35,91827 claims |
| Radius Health, Inc.Tymlos | $84 | $34,96813 claims |
| Johnson & JohnsonInvokana | $65 | $27,15516 claims |
| AbbVieSynthroid | $3,368 | $25,292293 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $14,9751,377 claims |
| Sanofi-aventis U.S. LLCLantus | $778 | $4,30232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
- Amber ChampionLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.